PFS · Company research
Provident Financial Services, Inc. (PFS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableFinancial Services
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Provident Financial Services, Inc. (PFS) Stock Price, News, Quote & History - Yahoo! Finance Canada | Provident Financial Services, Inc. (PFS) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 17, 2026 | neutral | 0 | 0.6 |
| Provident Financial Services (PFS): Buy, Sell, or Hold Post Q2 Earnings? - FinancialContent | Provident Financial Services (PFS): Buy, Sell, or Hold Post Q2 Earnings? FinancialContent | View source ↗ | FinancialContent | Oct 16, 2026 | neutral | 0 | 0.6 |
| Functional Prognostic Model Predicts CLL PFS With Ibrutinib/Venetoclax - The American Journal of Managed Care | Functional Prognostic Model Predicts CLL PFS With Ibrutinib/Venetoclax The American Journal of Managed Care | View source ↗ | The American Journal of Managed Care | Oct 15, 2026 | neutral | 0 | 0.6 |
| 1 Bank Stock on Our Buy List and 2 We Ignore - StockStory | 1 Bank Stock on Our Buy List and 2 We Ignore StockStory | View source ↗ | StockStory | Oct 15, 2026 | neutral | 0 | 0.6 |
| Provident Financial Services, Inc (NYSE:PFS) Stock Has Consensus Target Price of $26.79 According to Brokerages - MarketBeat | Provident Financial Services, Inc (NYSE:PFS) Stock Has Consensus Target Price of $26.79 According to Brokerages MarketBeat | View source ↗ | MarketBeat | Oct 14, 2026 | neutral | 0 | 0.6 |
| Tenumomeran/Raplemomeran Plus Pembrolizumab Misses PFS End Point in HPV16+ HNSCC - OncLive | Tenumomeran/Raplemomeran Plus Pembrolizumab Misses PFS End Point in HPV16+ HNSCC OncLive | View source ↗ | OncLive | Oct 13, 2026 | neutral | 0 | 0.6 |
| (PFS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily | (PFS) as a Liquidity Pulse for Institutional Tactics Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 13, 2026 | neutral | 0 | 0.6 |
| A Saskatchewan lithium project is estimated to need C$603 million before production - Stock Titan | A Saskatchewan lithium project is estimated to need C$603 million before production Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Southern Cross Gold Stock: Upcoming MRE, PFS But Low Upside For Now (OTCMKTS:SXGCF) - Seeking Alpha | Southern Cross Gold Stock: Upcoming MRE, PFS But Low Upside For Now (OTCMKTS:SXGCF) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 13, 2026 | neutral | 0 | 0.6 |
| PFS Hawksmoor Distribution A Inc (GB00B6TJCR05.L) latest stock news and headlines - Yahoo Finance UK | PFS Hawksmoor Distribution A Inc (GB00B6TJCR05.L) latest stock news and headlines Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 11, 2026 | neutral | 0 | 0.6 |
| Provident Financial Services, I (PFS) Stock Forecasts - Yahoo Finance | Provident Financial Services, I (PFS) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma - OncLive | Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma OncLive | View source ↗ | OncLive | Oct 8, 2026 | neutral | 0 | 0.6 |
| ArriVent’s phase 3 lung cancer trial flops, sinking stock - Fierce Biotech | ArriVent’s phase 3 lung cancer trial flops, sinking stock Fierce Biotech | View source ↗ | Fierce Biotech | Oct 6, 2026 | neutral | 0 | 0.6 |
| Provident Financial Services (NYSE:PFS) Stock Price - Simply Wall Street | Provident Financial Services (NYSE:PFS) Stock Price Simply Wall Street | View source ↗ | Simply Wall Street | Oct 6, 2026 | neutral | 0 | 0.6 |
| Carotuximab Plus Apalutamide Improves PFS in mCRPC - OncLive | Carotuximab Plus Apalutamide Improves PFS in mCRPC OncLive | View source ↗ | OncLive | Oct 6, 2026 | neutral | 0 | 0.6 |
| Provident Financial Services, Inc. Schedules Third Quarter Earnings Conference Call | Provident Financial Services, Inc. (NYSE: PFS) announced it will release third quarter 2026 financial results on October 28, 2026, followed by an investor conference call on October 29, 2026. The company, with $25.66 billion in assets as of June 30, 2026, operates banking branches across New Jersey, Pennsylvania, and New York, along with wealth management and insurance subsidiaries. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | neutral | 0 | 1 |
| Provident expects to release third-quarter results after market close Oct. 28. - Stock Titan | Provident expects to release third-quarter results after market close Oct. 28. Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Provident Financial Services (NYSE:PFS) Stock Crosses Above Two Hundred Day Moving Average - Should You Sell? - MarketBeat | Provident Financial Services (NYSE:PFS) Stock Crosses Above Two Hundred Day Moving Average - Should You Sell? MarketBeat | View source ↗ | MarketBeat | Sep 29, 2026 | neutral | 0 | 0.6 |
| Provident Financial Services (PFS) Stock May Be 47% Undervalued As Returns Support A Bargain - Yahoo Finance | Provident Financial Services (PFS) Stock May Be 47% Undervalued As Returns Support A Bargain Yahoo Finance | View source ↗ | Yahoo Finance | Sep 26, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.